Literature DB >> 25790842

AMH and AMHR2 polymorphisms and AMH serum level can predict assisted reproduction outcomes: a cross-sectional study.

Carla Peluso1, Fernando L A Fonseca, Guilherme G Gastaldo, Denise M Christofolini, Emerson Barchi Cordts, Caio P Barbosa, Bianca Bianco.   

Abstract

BACKGROUND: In human assisted reproduction, the ovarian response to exogenous recombinant Follicle-stimulating Hormone (FSH) therapy is variable and difficult to predict. The standard protocol of ovarian hyperstimulation can result in satisfactory response; however, an unsatisfactory response necessitates FSH dose adjustment or results in ovarian hyperstimulation syndrome (OHSS). Polymorphisms in AMH and AMHR2 genes appear to affect hormone biological activities, thus affecting follicle recruitment and development, leading to infertility. We aimed to evaluate AMH and AMHR2 polymorphisms in infertile women, and correlate those findings with AMH, FSH and estradiol serum level response to controlled ovarian hyperstimulation (COH), as well as assisted reproduction outcomes.
METHODS: A cross-sectional study comprising 186 infertile women that underwent one cycle of high complexity assisted reproductive treatment. Blood samples were collected and a TaqMan assay was used for AMH G146T/rs10407022 and AMHR2 A-482G/rs2002555, A10G/rs11170555, C1749G/rs2071558 and G4952A/rs3741664 genotyping, and FSH, estradiol and AMH levels were measured. The findings were correlated to human reproduction outcomes.
RESULTS: AMH rs10407022 and AMHR2 rs2002555 polymorphisms were not associated with hormonal measurements, whereas AMHR2 rs11170555 and rs3741664 were positively associated with AMH, estradiol and FSH levels. The genotype distribution of AMH and AMHR2 genes according to Controlled Ovarian Hyperstimulation did not show a positive association. However, an association with AFC, degree of oocyte maturation (allele G of AMHR2 rs2071558) the number of embryos produced (alleles T and G of AMH rs10407022 and AMHR2 rs2002555, respectively) and frozen embryo (allele G of AMHR2 rs11170555) were found to be statistically associated. Considering COH, serum AMH and AFC were a positive predictor to OHSS. Regarding serum AMH and assisted reproduction outcomes, a positive correlation with all variables studied was found. Comparing AFC and AMH as predictors of human reproduction outcomes, the AFC was less effective than serum AMH. Considering pregnancy rates, no marker was positively associated.
CONCLUSION: AMHR2 polymorphisms were associated with estradiol, AMH and FSH measurements, as well as number and quality of embryos, while AMH polymorphisms was associated with number of embryos produced. Serum AMH was correlated with nearly all variables analyzed in assisted reproductive treatment, demonstrating that it represents a better biomarker of OHSS and human reproduction outcomes compared to AMH and AMHR2 polymorphisms.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25790842     DOI: 10.1159/000373961

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  10 in total

1.  Can polymorphisms of AMH/AMHR2 affect ovarian stimulation outcomes? A systematic review and meta-analysis.

Authors:  Di Chen; Xiangyu Zhu; Jielei Wu
Journal:  J Ovarian Res       Date:  2020-09-04       Impact factor: 4.234

Review 2.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

3.  Association of AMH and AMHR2 gene polymorphisms with ovarian response and pregnancy outcomes in Indian women.

Authors:  Stacy Colaco; Swati Achrekar; Akshata Patil; Unnati Sawant; Sadhna Desai; Vijay Mangoli; Padma Rekha Jirge; Deepak Modi; Smita D Mahale
Journal:  J Assist Reprod Genet       Date:  2022-06-17       Impact factor: 3.357

4.  Involvement of single nucleotide polymorphisms in ovarian poor response.

Authors:  Sayyed Mohammad Hossein Ghaderian; Reza Akbarzadeh; Saghar Salehpour
Journal:  J Assist Reprod Genet       Date:  2021-05-29       Impact factor: 3.357

5.  Single-cell analysis of differences in transcriptomic profiles of oocytes and cumulus cells at GV, MI, MII stages from PCOS patients.

Authors:  Qiwei Liu; Yumei Li; Yun Feng; Chaojie Liu; Jieliang Ma; Yifei Li; Huifen Xiang; Yazhong Ji; Yunxia Cao; Xiaowen Tong; Zhigang Xue
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

6.  A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients.

Authors:  Lan Wu; Yazhou Sun; Jun Wan; Ting Luan; Qing Cheng; Yong Tan
Journal:  Mol Med Rep       Date:  2017-05-18       Impact factor: 2.952

7.  Anti-Müllerian Hormone Gene Polymorphism is Associated with Clinical Pregnancy of Fresh IVF Cycles.

Authors:  Cheng-Hsuan Wu; Shun-Fa Yang; Hui-Mei Tsao; Yu-Jun Chang; Tsung-Hsien Lee; Maw-Sheng Lee
Journal:  Int J Environ Res Public Health       Date:  2019-03-08       Impact factor: 3.390

8.  Association of two single nucleotide polymorphisms rs10407022 and rs3741664 with the risk of primary ovarian insufficiency in a sample of Iraqi women.

Authors:  Tamadher Abbas Rafaa; Ahmed AbdulJabbar Suleiman; Mustafa Falah Dawood; Ali Mohammed Al-Rawi
Journal:  Mol Biol Res Commun       Date:  2020-12

9.  AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation.

Authors:  Christian Cerra; William G Newman; Dalia Tohlob; Helen Byers; Gregory Horne; Stephen A Roberts; Lamiya Mohiyiddeen
Journal:  J Assist Reprod Genet       Date:  2016-05-03       Impact factor: 3.412

10.  The Relationship between AMH and AMHR2 Polymorphisms and the Follicular Phase in Late Reproductive Stage Women.

Authors:  Anna Jurczak; Małgorzata Szkup; Anna Grzywacz; Krzysztof Safranow; Elżbieta Grochans
Journal:  Int J Environ Res Public Health       Date:  2016-02-02       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.